

# The Influenza Pandemic of 2009

## Lessons and Implications

Paul Shapshak,<sup>1,2</sup> Francesco Chiappelli,<sup>3</sup> Charurut Somboonwit<sup>1,4</sup> and John Sinnott<sup>1,4</sup>

1 Division of Infectious Disease, Department of Internal Medicine, Tampa General Hospital, College of Medicine, University of South Florida, Tampa, FL, USA

2 Department of Psychiatry and Behavioral Medicine, College of Medicine, University of South Florida, Tampa, FL, USA

3 Division of Oral Biology and Medicine, UCLA School of Dentistry, Los Angeles, CA, USA

4 Clinical Research Unit, Hillsborough Health Department, Tampa, FL, USA

### Abstract

Influenza is a moving target, which evolves in unexpected directions and is recurrent annually. The 2009 influenza A/H1N1 pandemic virus was unlike the 2009 seasonal virus strains and originated in pigs prior to infecting humans. Three strains of viruses gave rise to the pandemic virus by antigenic shift, reassortment, and recombination, which occurred in pigs as ‘mixing vessels’. The three strains of viruses had originally been derived from birds, pigs, and humans. The influenza hemagglutinin (HA) and neuraminidase (NA) external proteins are used to categorize and group influenza viruses. The internal proteins (PB1, PB1-F2, PB2, PA, NP, M, and NS) are involved in the pathogenesis of influenza infection. A major difference between the 1918 and 2009 pandemic viruses is the lack of the pathogenic protein PB1-F2 in the 2009 pandemic strains, which was present in the more virulent 1918 pandemic strains. We provide an overview of influenza infection since 1847 and the advent of influenza vaccination since 1944. Vaccines and chemotherapy help reduce the spread of influenza, reduce morbidity and mortality, and are utilized by the global rapid-response organizations associated with the WHO. Immediate identification of impending epidemic and pandemic strains, as well as sustained vigilance and collaboration, demonstrate continued success in combating influenza.

### 1. Pandemic Influenza Overview

On an annual basis, influenza epidemics affect 5–15% of the world’s population, and severe illness occurs in about 5 million people worldwide. There are 250 000–500 000 deaths annually that are attributable to influenza virus and its complications. In the US, there are estimates of 200 000 hospitalizations and approximately 36 000 deaths due to seasonal influenza per year.<sup>[1-3]</sup>

The 2009 outbreak of influenza A/H1N1 virus, originally referred to as ‘swine flu’, was a pandemic caused by a novel strain of influenza virus. The exact source of this outbreak is unclear, but most likely there was a link between influenza cases in North America and an earlier outbreak of late-season influenza cases in Mexico. Influenza infections in Mexico were initially reported from March 24 through to April 24, 2009. Ninety-eight patients were hospitalized for acute respiratory illness at the National Institute of Respiratory Diseases in Mexico City with confirmed novel swine-origin influenza A

virus (S-OIV) H1N1 infection.<sup>[1-7]</sup> In May 2009, the WHO raised its pandemic alert level to ‘phase 5’ out of a maximum of 6, as a signal that a pandemic was imminent. Promptly, on June 12, 2009, a full ‘phase 6’ pandemic was declared by the WHO.<sup>[4]</sup>

The Centers for Disease Control and Prevention (CDC) estimated on April 19, 2010, that from April 2009 to March 2010 there were between 43 and 88 million cases of 2009 H1N1 pandemic influenza, between 192 000 and 398 000 hospitalizations, and between 8720 and 18 050 deaths. In addition, the CDC concluded that there had actually been two waves of infection in 2009; one early (in spring) and one late (in the fall). Moreover, while the pandemic in North America waned, there were areas in West and Central Africa that continued to show transmission. In addition, there were low levels of circulation across Northern Europe, Eastern Europe, and Asia. Globally, there were 1 483 520 cases and 25 174 deaths.<sup>[8-11]</sup> On August 10, 2010, the WHO declared an end to the 2009 influenza A/H1N1 pandemic.<sup>[12]</sup>

## 1.1 Disease Synopsis

Influenza tends to occur in colder months in temperate zones and year-round in tropical zones.<sup>[13-15]</sup> During influenza infections, pre-existing medical problems are exacerbated (including lung and heart diseases, diabetes mellitus, cancer, and kidney problems), and when death occurs it is most often caused by bacterial pneumonia. Bacterial superinfections include streptococcal and staphylococcal infections.<sup>[16,17]</sup> Generally, influenza infections last a week as part of a severe malaise; symptoms include fever, myalgia, headache, non-productive cough, sore throat, and rhinitis. Recovery for the most part is spontaneous, although severe illness and death occur in high-risk populations, including infants, pregnant women, the elderly, persons with chronic or serious medical conditions including gross obesity, the immunocompromised, and indigenous populations.<sup>[18]</sup>

Initially, during the 2009 influenza pandemic in the US, patients exhibited fever, cough, respiratory distress, increased serum lactate dehydrogenase levels, and bilateral patchy pneumonia, and some patients developed life-threatening respiratory failure.<sup>[5,19]</sup> The most frequently reported symptoms at presentation were fever, cough, and sore throat, with significant reports of diarrhea and vomiting. Patient ages ranged from 3 months to 81 years; however, surprisingly, healthy teenagers and young and middle-aged adults (more than half between the ages of 13 and 47 years) were primarily affected. Sixty percent of the patients were 18 years of age or younger, 16% were of school age, and 18% had traveled to Mexico. About 9% of the patients required hospitalization and in the initial report there were two deaths.<sup>[4]</sup> In New York City, there were some differences in transmissibility patterns compared with prior pandemics. For example, the transmissibility of the 2009 pandemic H1N1 influenza virus in households was lower than for past pandemics, and transmission occurred around the time of symptom onset in each index patient. Furthermore, susceptibility within households was inversely proportional to the number of members in the households.<sup>[20]</sup>

## 1.2 Swine Reservoirs

Influenza viruses infect pigs, birds, and humans, and viruses found in pigs can be derived from all three sources. Viruses from pigs and birds are divided into three groups: avian, classical swine, and 'avian-like' swine viruses. All influenza viruses require cell surface receptor oligosaccharides with a terminal sialic acid, although there are differences among these receptors in various species. However, pigs appear unique because in

their trachea, they have receptors for human and avian influenza viruses in addition to swine influenza virus receptors. Thus, viruses from all three sources can bind to and infect pig trachea and potentially exchange genetic sequences to produce new viral strains. Consequently, pigs are considered to be mixing vessels in which new strains of virus are produced.<sup>[21]</sup> Influenza virus infection of pigs was first recognized symptomatically during the Spanish influenza pandemic in the summer of 1918 and the virus was first isolated from pigs in 1930.<sup>[22,23]</sup>

The genetic makeup of swine influenza viruses in pig populations can be significantly different throughout the world despite similar hemagglutinin (HA) and neuraminidase (NA) subtypes.<sup>[24]</sup>

In the US, swine influenza A/H1N1 showed little change among pig herds for 60 years (from the 1930s to the 1990s). However, by the late 1990s, for unknown reasons, swine influenza A/H1 virus evolution widened to include H1N2 with continued spread of H1N1. There was also increased cross-species mobility, with sporadic infections of people with swine influenza A/H1N1.<sup>[25]</sup> The genes constituting influenza viruses isolated from US pigs originated from three different hosts (humans, swine, and birds): (i) HA, NA, and RNA polymerase subunit B1 (*PBI*) genes from human influenza virus; (ii) matrix (*M*), non-structural protein (*NS*), and nucleoprotein (*NP*) genes from swine-lineage H1N1 viruses; and (iii) RNA polymerase subunit A (*PA*) and subunit B2 (*PB2*) genes from an avian source.<sup>[26]</sup> These viral strains circulated in US pig farms and an increased rate of genetic change occurred between H1 and H3 subtypes.<sup>[4,27-29]</sup> Further evolution occurred so that after 1998, H3N2 virus emerged in US pig populations.<sup>[30]</sup> Additionally, H3N3 and H1N1 avian influenza virus subtypes were isolated from pigs in Canada.<sup>[31]</sup> By early 2009, as a prelude to the pandemic, an H1N1 virus further evolved and established successful human-to-human transmission.<sup>[25]</sup> There were reports of H3N1 viruses circulating in Asia and the US, and an H1N1 virus composed of only human influenza virus genes entered the US pig population.<sup>[4,27-29]</sup>

Changes occurred in swine influenza in Europe contemporaneously with changes in the US. In Europe in 1979, swine influenza viruses possessing avian genes were first detected and were rampant in pig farms until 2000. At that time, for example, the circulating H3N2 swine strains that carried A/Port Chalmers/1/73-like surface glycoproteins originated from human-avian-related virus strains that emerged across Europe in 1983–85. Approximately one in five teenagers and young adults between the ages of 15 and 29 who had contact with pigs became infected as well. Although infections with this particular swine virus strain possessing avian-derived internal genes

were relatively mild, it signaled danger that new strains could enter humans more frequently than previously thought.<sup>[25,32]</sup>

## 2. Molecular Virology

Influenza viruses belong to the genus *Orthomyxovirus* in the family *Orthomyxoviridae*. There are eight individual segments of negative sense RNA that comprise the viral genome, and each encodes at least one gene product.<sup>[13,33]</sup> The functions of the eight RNA segments of the influenza virus are shown in table I. Table II shows the genotypes that compose the 2009 human pandemic H1N1 (novel S-OIV). The viral RNA segments of this triple reassortant are phylogenetically related to human, pig, and avian sources.<sup>[4]</sup>

The influenza virus genome is subject to antigenic (or genetic) ‘drift’, which is defined as changes that occur gradually as point mutations accumulate. This is caused by the absence of a proof-reading mechanism for the polymerase. In contrast, antigenic ‘shift’ is typically attributed to reassortment of the eight viral segments, including recombinatory events resulting in quantum leaps of more extensive and abrupt changes in viral genotypes. When this occurs, the human population shows greater immunologic naïveté to such proliferating viruses.<sup>[13,33,46,47]</sup> Influenza virus recombination occurs within influenza virus genes when at least two viral strains infect a cell and RNA sequences from the infecting strains are recombined or exchanged. This can then be followed by shuffling or reassortment of the various parental and progeny RNA molecules among the emergent viruses. This is a means of influenza strain change or evolution.<sup>[33,46,48]</sup>

**Table I.** Influenza A RNA segments, genes, and protein functions<sup>[13,34-44]</sup>

| RNA segment | Gene             | Proteins: functions                                       |
|-------------|------------------|---|
| 1           | HA               | Hemagglutinin: cell attachment                            |
| 2           | NA               | Neuraminidase: cell detachment                            |
| 3           | NP               | Nucleoprotein: binds to viral RNA                         |
| 4           | M <sup>a</sup>   | Matrix proteins M1, M2: ion channel, spans lipid bilayer  |
| 5           | NS <sup>a</sup>  | Non-structural proteins NS1, NS2: occur only within cells |
| 6           | PA               | RNA polymerase subunit: cap-snatching endonuclease        |
| 7           | PB1 <sup>b</sup> | RNA polymerase subunit                                    |
| 8           | PB2              | RNA polymerase subunit: cap-binding                       |

a The *M* and *NS* genes produce multiple proteins encoded by separate reading frames.

b The *PB1* gene produces a pro-apoptotic protein, PB1-F2, which contributes to the virulence of primary influenza and promotes secondary bacterial infections. This virulence factor was present in the 1918 epidemic and may have been absent or exhibiting reduced function in the 2009 pandemic.

**Table II.** Origins of genes found in the 2009 novel swine-origin influenza A virus (S-OIV).<sup>[4,36,45]</sup> The genes of this pandemic triple reassortant virus were phylogenetically related to viruses derived from pigs, birds, and humans

| Gene <sup>a</sup> | Phylogenetic lineage relatedness      |
|-------------------|---------------------------------------|
| HA                | Classic swine, North American lineage |
| NA                | Eurasian swine lineage                |
| NP                | Classic swine, North American lineage |
| M                 | Eurasian swine lineage                |
| NS                | Classic swine, North American lineage |
| PA                | Avian, North American lineage         |
| PB1               | Seasonal human H3N2                   |
| PB2               | Avian, North American lineage         |

a Gene functions are described in table I.

### 2.1 Virulence

Several influenza virus-induced molecular pathways contribute to virulence by causing overall damage to the infected cell, often resulting in cell death. Recombination and reassortment processes of influenza gene segments result in changes in viral virulence due to nucleotide sequence changes.<sup>[48]</sup> Modern molecular virologic techniques, including reverse genetics, can reconstruct influenza strains. Reverse genetics utilizes cloned viral genes for transcription to produce virus-related RNA and is of particular use when highly pathogenic avian influenza viruses are genetically manipulated for characterization and attenuation,<sup>[49]</sup> and we present several examples. This technology has been used to produce progeny virus derived from the pandemic 1918 influenza virus and a contemporary human H1N1 virus (A/Kawasaki/173/2001/K173). Progeny virus virulence was assessed in ferrets and an isolate, 1918PB1/K173, which expressed the 1918 nucleoprotein and RNA polymerase complex (PB2, PB1, and PA) showed virulence in ferret upper and lower respiratory tracts. This work supported the involvement of these genes in the virulence of the 1918 pandemic viruses.<sup>[50]</sup> Reverse genetics technology also produced Spanish influenza virus strains showing aberrant (reduced) immune responses in mice and non-human primates, pathogenic characteristics these strains shared with H5N1 viruses. The virus showed additional virulence factors that included features of the replication complex, NS1 protein, and PB1-F2 proteins, whereas virus transmissibility was related to HA and PB2 proteins.<sup>[36]</sup> Influenza virus demonstrates a striking molecular feature: its ability to steal messenger RNA (mRNA) 5' caps from host cells. A 5' cap is required for eukaryote mRNA translation, and influenza mRNA requires a 5' cap for translation as well. This molecular theft process is carried out by the RNA polymerase complex. It involves direct interactive forces and synergistic activities of the viral PB2,

PB1, and PA polymerase subunits and probably does not involve other host proteins.<sup>[34,37,38]</sup> This parasitic feature subverts the host's molecular machinery to produce influenza proteins, and infected cells become factories for influenza virus production until the cells die. 5' cap production is a potential target for anti-viral therapy and needs further study. Additional studies showed that the PB1-F2 protein is implicated in mechanisms of pathogenicity as well as subsequent susceptibility to bacterial infection. Its presence is linked to the 1918 influenza virus and may have been absent or inactive in recent influenza strains. However, there is a continual danger of more virulent progeny strains emerging due to this protein.<sup>[37,38,42-44,51]</sup>

Apoptosis is another source of virulence and plays an important role in pathogenesis as alveolar epithelial cells succumb to apoptosis due to influenza infection. Studies in a murine model of influenza-induced pneumonia indicate that the mechanism of this process involves direct effects of influenza proteins (e.g. PB1-F2) as well as release of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) from infiltrating phagocytic macrophages.<sup>[36,52-54]</sup> Virulence studies at the protein structure level indicate that particular amino acid signatures in viral proteins might be specific for host range and severity of influenza infections, and indicative of viruses that become pandemic. For example, amino acid mutations in several viral proteins that were conserved in past epidemic influenza strains may be determinants of the severity of influenza infections as well as host range.<sup>[55-58]</sup> In addition, the 1918 HA is activated by the pulmonary cell proteases TMPRSS2 and TMPRSS4 (transmembrane protease, serine 2 and 4), which may be part of its pathogenic mechanism of spread within lungs.<sup>[4,59-61]</sup>

## 2.2 Emergence of Influenza Virus Strains

A key general mechanism for the emergence of virulent influenza strains, including those involved in the pandemics of 1918, 1957, 1968, and 2009, involved chromosomal changes due to reassortment.<sup>[62-64]</sup> The emergence of the 2009 pandemic influenza A virus involved the accumulation of gene segments phylogenetically related to influenza from three species, as stated (table II). H1N1 HA, NP, NA, M, and NS were from pigs, H1N1 PB2 and PA were from birds, and H3N2 PB1 was from humans. Moreover, the pandemic RNA segments derived originally from pigs were phylogenetically related to those of influenza A viruses circulating in pig populations in Eurasia and North America.<sup>[4,25,45,62]</sup> Pandemic 2009 influenza A/H1N1 has no similarity to seasonal 2009 influenza A/H1N1 and may have circulated undetected for some time prior to detection.

Interestingly, its low genetic diversity supports a model of infection of humans due to a single event or due to multiple infections by similar viruses.<sup>[45]</sup> The HA and NA genes are generally utilized in surveillance and classification of influenza types and subtypes, and are key components in identifying emergent viral strains. These and other genes are used to characterize changes in sequence patterns and reassortment events as well.<sup>[1,13,47,65-67]</sup> A sequence analysis of several hundred H1N1 viruses ranging from the 1918 pandemic to the 2009 pandemic (i.e. 91 years) demonstrated that HA is the drift-defining antigen for H1N1 viruses, due to host selection from 1918 to 2008.<sup>[47]</sup> This study specifically defined two amino acid sites in HA, 156 and 190, which showed strong positive selection and sequence diversification, due to host immunity since 1918. In addition, amino acid 190 and the amino acid at another site, 225, were critical receptor-binding determinants. The study also showed that the influenza of the 1918 pandemic had undergone antigenic drift at amino acids 190 and 225. However, during the 2009 pandemic, the 190 and 225 amino acid sites were highly conserved and it was concluded that these sites had not been subject to selection at that time.<sup>[47]</sup>

*In vitro* and field studies indicate that emergence of new influenza strains involving reassortment may not be stochastic. For example, an *in vitro* examination of cultured mixtures of A/WSN/33 (H1N1) and A/Duck/Czechoslovakia/56 (H4N6) viruses did not produce randomly assorted genes in progeny viruses but, rather, produced progeny that depended on protein interactions during the assembly of viral particles. Specifically, progeny viruses predominantly had the HA gene from A/WSN/33 (H1N1) virus and the NP gene from A/Duck/Czechoslovakia/56 (H4N6).<sup>[68]</sup> Field studies of internal genes PB1, PB2, PA, NP, M, and NS from avian and human influenza showed that an avian PB1 gene reassorted into human H3N2 and H2N2 influenza isolates. A full factorial laboratory analysis showed that of the possible combinations of PB1, PB2, NP, and PA from avian H5N1 and human H1N1 viruses, the strongest polymerase activity in human cells was due to the combination of H1N1 PB2 and H5N1 PB1 genes. This combination also produced the greatest number of mutant progeny *in vitro*.<sup>[35]</sup> In other work, non-stochasticity of the reassortment process of the gene sequence was studied for swine influenza virus genes using statistical techniques (termed Rao, Shannon, and Renyi entropies).<sup>[63]</sup> The results supported findings in human viruses that HA and NA, as well as PB1 genes, tended to associate during reassortant production. Possible mechanisms resulting in preferential reassortants might include interactions during virion packaging, morphogenesis, and budding. This may impose selective pressure on these RNA segments and

selection of compensatory mutants due to interactions among these viral proteins.<sup>[63,69]</sup> Possible additional biases were noted, including sampling bias (since most of the human sequences analyzed were derived from New York State and New Zealand), population stratification, and exponential growth and bottleneck tendencies of viral populations.<sup>[63]</sup> Suffice it to say, the task of defeating influenza virus would be improved through studies of non-stochastic evolutionary processes.<sup>[70]</sup> One could then devise rules for production of reassortant progeny and perhaps predict evolutionary trends.

### 2.3 Phylogenetic Analysis

We present a phylogenetic analysis of the H1N1 novel S-OIV in relation to other contemporary strains of influenza. Figures 1 and 2 show the phylogenetic trees of two of eight S-OIV genes with their immediate predecessors (nearest neighbors), which predominantly come from swine influenza viruses sampled between 1999 and 2007. A major limitation of any such analysis is the scope of sequence data available. The survey data is often patchy and at times insufficient for reliable reconstruction of events leading to the emergence of a major new variety of the virus. It is especially evident in the cases of multiple host and subtype transitions such as the emergence of S-OIV, and there are insufficient swine-derived virus samples to resolve some of these issues. Similarly, since many early cases of S-OIV in humans were not captured in the available sequence record, it is unclear how long a period of 'cryptic transmission' may have occurred.<sup>[2]</sup> An important question is how S-OIV influenza virus competed during co-circulation with seasonal H1N1 and H3N2 viruses. Overall, expanding survey systems in terms of geography, density, and diversity is an issue of utmost importance. Thus, the difficult goals of researchers and clinicians are to describe what strains are current at any point in time and to attempt to predict the strains that may lead to epidemics and pandemics.

The complete set of phylogenetic trees of eight influenza genes is shown in figure S-1 in Supplemental Digital Content 1 (available online at <http://links.adisonline.com/MDZ/A2>). These alignments included 259 *PB2* sequences, 251 *PB1* sequences, 242 *PA* sequences, 501 *HA1* sequences, 1327 *NP* sequences, 439 *NA* sequences, 398 *M2* sequences, and 283 *NS2* sequences.

### 2.4 Influenza Molecular Chronology


Molecular research, including phylogenetic studies, suggests that most likely, the *HA* gene was highly variable for several thousand years to the present day. The parental *HA* gene gave rise to influenza A and B virus *HA* genes approximately

4000 years ago and the influenza parental *HA* gene had diverged from the influenza C virus hemagglutinin-esterase (*HE*) gene before that, approximately 8000 years ago.<sup>[71,72]</sup> Historical studies, alone, indicate that there were probably already influenza epidemics when the academic record commenced. Piero Bouoninsegni of Florence first used the term influenza in 1580, though other names were used prior to that. Hippocrates referenced one of the earliest influenza epidemics as having occurred in approximately 412 BCE. Later chronicles described influenza epidemics in 877 CE and intermittently until 1386 CE. Since then, influenza epidemics have been reported at increased rates.<sup>[73,74]</sup>


Table III provides an overview of several key influenza strains (and vaccines) during selected periods since 1847 and is not an exhaustive tabulation or complete history of influenza infections.<sup>[75-78]</sup> Here we mention a few key points related to this table. In 1918–1919, the 'Spanish flu' pandemic caused 675 000 deaths in the US and there were 50–100 million deaths worldwide. There were three waves, with a mortality rate of 0.1% typical for influenza infection in the first wave and 2.5% in the second and third waves (a 25-fold increase). During this period, no influenza virus vaccines were produced. However, bacterial vaccines were produced by Cadham and many others in an effort to prevent mortality from coincident bacterial infections and pneumonia.<sup>[79,120]</sup> Cadham's vaccine included an unidentified bacterium specifically isolated from individuals with influenza.<sup>[16,17,78-80]</sup>

After the 1918–1919 pandemic, in the periods from 1920 to 1940, 1948 to 1949, 1959 to 1967, 1970 to 1976, and 1990 to 1996, there were continued influenza infections with patterns of lesser virulence, and no pandemics.<sup>[1,76]</sup> In the Asian influenza pandemic of 1957, besides morbidity in persons greater than 70 years of age, the virus infection itself was often lethal, and in the US, there were 86 000 deaths.<sup>[1,36,121]</sup> After initial recognition as influenza A, it was found that both the HA and NA antigens were different from any influenza previously found in humans and the subtype was later identified as H2N2. The new virus was shown to have high sialidase/neuraminidase activity that was more stable than that of earlier strains and this appeared to promote virus infection, replication, and spread.<sup>[1,122]</sup>

In 1968, the Asian influenza virus (H2N2) disappeared, 11 years after its appearance, and was replaced by the 'Hong Kong flu' (H3N2). Initially, this new pandemic progressed throughout Asia and the illness seemed to be milder, without the increased death rate that occurred when it spread in Western Europe. It also spread to the West Coast of the US and its severity increased during the next year of the pandemic in the US, with high illness and death rates; there were 56 300 deaths



**Fig. 1.** Phylogenetic tree of the hemagglutinin 1 (HA1) gene of influenza A virus, showing 2009 novel swine-origin influenza A virus (S-OIV) [or '2009 swine flu'] and nearest neighbors. S-OIV 2009 outbreak sequences are indicated in red. The nearest sequence neighbors of S-OIV sequences are indicated as follows (color and host are stated, respectively): black, swine; blue, avian; green, human. Human influenza A S-OIV sequences available from the National Center for Biotechnology Information (NCBI) Influenza Virus Resource as of July 1, 2009, were used for phylogenetic analysis.<sup>[2]</sup> The resulting alignment included 501 HA1 sequences. The methods are detailed in the legend of figure S-1 in Supplemental Digital Content 1. (Provided by Yuri Wolf, PhD, and Anastasia Nikolskaya, PhD, of the NCBI [Bethesda, MD, USA].)



**Fig. 2.** Phylogenetic tree of the neuraminidase (NA) gene of influenza A virus, showing 2009 novel swine-origin influenza A virus (S-OIV) [or '2009 swine flu'] and nearest neighbors. S-OIV 2009 outbreak sequences are indicated in red. The nearest sequence neighbors of S-OIV sequences are indicated as follows (color and host are stated, respectively): black, swine; blue, avian; green, human. Human influenza A S-OIV sequences available from the National Center for Biotechnology Information (NCBI) Influenza Virus Resource as of July 1, 2009, were used for phylogenetic analysis.<sup>[2]</sup> The resulting alignment included 439 NA sequences. The methods are detailed in the legend of figure S-1 in Supplemental Digital Content 1. (Provided by Yuri Wolf, PhD, and Anastasia Nikolskaya, PhD, of the NCBI [Bethesda, MD, USA].)

**Table III.** Overview of influenza strain and vaccine chronology<sup>a</sup>

| Year    | Epidemic and pandemic strains  | Vaccine strains  | Comments  | References     |
|---------|--|--|---|----------------|
| 1847    | A (H1N1) possibly  | None   | Possible cross-reaction with Spanish flu  | 74,75          |
| 1889–90 | A (H3N8) possibly<br>A (H2N2) possibly   | None   | Asiatic (Russian) influenza, originating probably in the Kirghiz steppes  | 74-77          |
| 1915    | A (H1N1) possibly  | None   |   | 78             |
| 1918–9  | A (H1N1) possibly  | A Canadian vaccine produced in 1918 was helpful but was against bacterial infections | Spanish flu. One third of the world's population was infected (0.5 billion) and 50–100 million people died. Elderly showed greater immunity. Overall, subsequent influenza strains (including H1N1, H2N2, and H3N2) were descended from this pandemic (excluding H5N1 and H7N7)   | 17,36,75,78-81 |
| 1944–5  | A/USA:Huston/AA/1945 H1N1  | A/USA:Huston/AA/1945 H1N1  | Possibly first influenza vaccines   | 82-86          |
| 1946–7  | A/Melbourne/1-MA/1946 H1N1<br>A/Cameron/1946 H1N1<br>A/Nevada/AF1946/2008 H1N1<br>A/Swine/Iowa/1946 H1N1<br>A/Chicken/Kalanit/1946/04 H9N2 | H1N1: A/PR8, A/Influenza virus/1947, A/Weiss, B/Lee                                  | Several vaccines tested that failed probably because of lack of cross-reaction. Virus isolates from humans, swine, and chickens indicated wider zoonotic risks  | 85,87,88       |
| 1950–1  | A/Liverpool/H3N2<br>A/Scandinavia/H1N  | Strains not stated   | H1N1 strains showed slight drift from 1918 strains. Liverpool (A/H3N2) strain more pathogenic than Scandinavian strain. Liverpool strain was associated with severe illnesses and high death rates in Great Britain, Canada, southern Europe, and Mediterranean countries. In England, the death rate was greater than in 1918. Elderly showed greater immunity | 89             |
| 1957–8  | A (H2N2) strains not stated  | Strains not stated.<br>17 million doses used in the US                               | Asian flu. Emerged in China and Hong Kong and spread worldwide. H2N2 strain killed 1–4 million people globally and about 70 000 in the USA. Conclusion: too little, too late. These were the virulent strains accidentally sent to laboratories worldwide and then retrieved  | 1,17,81,90,91  |
| 1968–9  | A/Aichi/2/1968 H3N2  | H3N2: A2/Aichi/2/68; A2/HK/68; A2/Mtl/68 B/Mass/66; B/Can/66                         | Hong Kong flu. Several vaccines tested that differed in effectiveness in various countries  | 17,81,92-94    |
| 1976    | A/New Jersey/76 (Hsw1N1)<br>A/Victoria/75 (H3N2)   | A/Port Chalmers/1/73 (H3N2)<br>A/Scotland/840/74 (H3N2)<br>B/Hong Kong/15/72         | Swine flu H1N1 and H3N2 infection detected at Fort Dix, NJ, USA   | 95             |
| 1977–9  | A/USSR/77 (H1N1)<br>A/Texas/1/77 (H3N2)<br>A/USSR/90/77 (H1N1)   | A/New Jersey/76 (swine flu) and A/Victoria/75 (H/N not identified)                   | Split bivalent vaccine used (H/N not stated). Russian flu (May 1977) appeared in northeastern China and spread south as well as northwest to Russia. Also resembled strains circulating in 1947–1956 (A/FW/1/50 (H1N1)). Strains A/Texas/1/77 (H3N2) and A/USSR/90/77 (H1N1) were isolated in the USA, e.g. Wisconsin   | 3,96-103       |

Continued next page



Table III. Contd

| Year   | Epidemic and pandemic strains   | Vaccine strains   | Comments  | References     |
|--------|---|---|---|----------------|
| 1977   | A (H5N1)<br>A/USSR/90/77 (H1N1)   | A/USSR/90/77 (H1N1)   | Avian influenza (chickens) H5N1<br>Influenza (humans) H1N1.<br>Note the human H5N1 epidemic that occurred 20 years later  | 36             |
| 1987–9 | A/Shanghai/11/87-like   | A/Leningrad/360/86  | Chemotherapy did not assist vaccine use   | 104,105        |
| 1997–8 | A/HongKong/156/97 (H5N1)<br>A/Duck/Singapore/3/97 (H5N3)<br>A/Mallard/Pennsylvania/10218/84 (H5N2)  | H5N1 and additional vaccines used<br>(as mentioned below for each period)   | H5N1, an avian influenza, circulated among humans in Eurasia, spread to more than 60 countries, infected 394 people, was highly pathogenic, and killed 248 people in China, Vietnam, Indonesia, and Egypt. Note that the chicken epidemic of H5N1 occurred 20 years earlier   | 3,36,106-111   |
| 2001–2 | A/Kawasaki/173/2001 (H1N1)  | A/New Caledonia/20/99-like (H1N1),<br>A/Moscow/10/99-like (H3N2),<br>B/Sichuan/379/99-like antigens.<br>For the B/Sichuan/379/99-like antigen, they used one of the antigenically equivalent viruses:<br>B/Johannesburg/05/99,<br>B/Victoria/504/2000, or<br>B/Guangdong/120/2000 | For vaccine production, in addition to H1N1 vaccine strains stated, instead of the A/Moscow/10/99-like (H3N2) strain, US manufacturers used the antigenically equivalent A/Panama/2007/99 (H3N2) virus. Viruses were selected within antigenically related groups for vaccine production because of their growth properties | 50,109         |
| 2002–3 | A/Denmark/6/2002(H3N2)  | A/New Caledonia/20/99 (H1N1);<br>A/Panama/2007/99 (H3N2)  | Vaccine strains were an A/Moscow/10/99-like virus and B/Hong Kong/330/2001-like virus   | 85,109,112,113 |
| 2003–4 | A/Wyoming/03/2003 (H3N2)<br>A/Finland/170/2003 (H3N2)<br>A/Wellington/03/2003 (H3N2)<br>A/Swine/Haseluenne/IDT2617/2003 (H1N1)  | A/New Caledonia/20/99 (H1N1);<br>A/Panama/2007/99 (H3N2),<br>B/Hong Kong/330/2001-like virus  | Vaccine strain was an A/Moscow/10/99 (H3N2)-like virus. The influenza B virus vaccines were either B/Hong Kong/330/2001 or B/Hong Kong/1434/02  | 85,109,113,114 |
| 2004–5 | A/Vietnam/1196/2004 (H5N1)<br>A/Denmark/15-02/2004 (H3N2)<br>A/Mississippi/5/2004 (H3N2)<br>A/Tiger/Thailand/CU-T3/2004 (H5N1)<br>A/Turkey/Ohio/313053/2004 (H3N2)<br>A/Chicken/Viet Nam/33/2004 (H5N1)<br>A/Chicken/Gujarat/3697/2004 (H9N2) | A/New Caledonia/20/99 (H1N1);<br>A/Wyoming/03/2003 (H3N2),<br>B/Shanghai/361/2002-like virus  | Vaccine strain was an A/Fujian/411/2002-like virus. The influenza B virus vaccine used B/Jiangsu/10/2003 or B/Jilin/20/2003. Here we see exemplified the wide range of influenza strains identified, not all of which match the vaccine strains used  | 85,109         |
| 2005–6 | A/Wisconsin/67/2005 (H3N2)<br>A/Zhejiang/199/2005 (H3N2)<br>A/Indonesia/5/2005 (H5N1)<br>A/Swine/Cotesd'Armor/016007/2005 (H1N1)<br>A/Thailand/RPFE/2005 (H5N1)   | A/New Caledonia/20/99 (H1N1)-like virus;<br>A/California/7/2003 (H3N2)-like virus;<br>B/Shanghai/361/2002-like virus  | As above, a wide range of influenza strains was identified, not all of which match the vaccine strains used   | 85,109         |

Continued next page

Table III. Contd

| Year             | Epidemic and pandemic strains  | Vaccine strains  | Comments   | References       |
|------------------|--|--|--|------------------|
| 2006–7           | A/Human/Iraq/207-NAMRU3/2006 (H5N1)<br>A/Paris/PA-6V-355/2006 (H3N2)<br>A/Virginia/UR06-0021/2007 (H3N2)<br>A/Shorebird/Delaware Bay/332/2006 (H7N3)<br>Influenza B virus (B/St. Petersburg/14/2006)<br>A/Cygnus cygnus/Iran/754/2006 (H5N1)<br>A/Chicken/Egypt/960N3-004/2006 (H5N1)<br>A/Chicken/Navapur/India/7966/2006 (H5N1)  | A/New Caledonia/20/99 (H1N1)-like virus;<br>A/Wisconsin/67/2005 (H3N2)-like virus (A/Wisconsin/67/2005 and A/Hiroshima/52/2005);<br>B/Malaysia/2506/2004-like virus<br>B/Malaysia/2506/2004 and B/Ohio/1/2005 strains  | A wide range of influenza strains was identified, not all of which match the vaccine strains used, as above  | 85,109           |
| 2007–8           | A/Colorado/UR06-0023/2007 (H3N2)<br>A/Chicken/Egypt/2628-1/2007 (H5N1)<br>A/USA:Texas/UR06-0195/2007 (H1N1)<br>A/Chicken/Yunnan/Zhaotong07/2007 (H9N2)<br>A/Giant anteater/Tennessee/UTCVM07-733/2007 (H1N1)<br>A/Mallard duck/Minnesota/Sg-00121/2007 (H1N1)  | A/Solomon Islands/3/2006 (H1N1)-like virus;<br>A/Wisconsin/67/2005 (H3N2)-like virus;<br>B/Malaysia/2506/2004-like virus   | Imperfectly matched vaccines vs infective strains. Additional H1N1 strains added to the UniProt database   | 3,85,109         |
| 2008–9           | A/Chicken/Laos/1/2008 (H5N1)<br>A/Idaho/ID-2008/2003 (H3N2)<br>A/Stockholm/6/2008 (H1N1)<br>B/Kisumu/6910/2008<br>B/Pennsylvania/PIT56/2008  | A/Brisbane/59/2007 (H1N1)-like virus;<br>A/Brisbane/10/2007 (H3N2)-like virus;<br>B/Florida/4/2006 and B/Brisbane/3/2007.<br>Both are B/Florida/4/2006-like viruses  | Imperfectly matched vaccines vs strains. B-virus vaccines used predominately in the Southern Hemisphere  | 85,109           |
| May 2009–present | A/New York/3059/2009 (H3N2)<br>A/Argentina/Malbran017/2009 (H1N1)<br>A/Brandenburg/19/2009 (H1N1)<br>A/GuangzhouSB/01/2009 (H1N1)<br>A/Reassortant/IDCDC-RG15(Texas/05/2009 x Puerto Rico/8/1934) (H1N1)<br>A/Reassortant/IDCDC-RG18(Texas/05/2009 x New York/18/2009 x Puerto Rico/8/1934) (H1N1)<br>A/Reassortant/IDCDC-RG22(New York/18/2009 x Puerto Rico/8/1934) (H1N1)<br>A/Reassortant/NIBRG-121(California/07/2009 x PR8) (H1N1) | A/Brisbane/59/2007 (H1N1), a current vaccine virus;<br>A/South Dakota/6/2007 (H1N1) (an A/Brisbane/59/2007-like virus)<br>current vaccine virus used in live attenuated vaccines.<br>A/Brisbane/10/2007 (H3N2) and A/Uruguay/716/2007 (H3N2) (A/Brisbane/10/2007-like viruses) | Influenza appeared in USA, Mexico, Australia, etc. and already shows extensive resistance to the anti-influenza drug oseltamivir (Tamiflu). Human-to-human transmission. Pandemic declared in June 2009. Reassortant genes from swine, birds, and humans. A few examples of current viruses, reassortants, and vaccine viruses shown | 3,4,25,36,85,109 |

Continued next page

**Table III.** Contd

| Year   | Epidemic and pandemic strains   | Vaccine strains  | Comments  | References |
|--------|---|--|---|------------|
|        | A/Reassortant/NYMC X-179A(California/07/2009 x NYMC X-157) (H1N1)<br>Novel strain 2009 H1N1 | Reassortant vaccine virus NYMC X-179A, derived from the A/California/7/2009 (H1N1) virus   | 15 µg of hemagglutinin protein. Raised antibody titer to 1:40 by 21 days post-vaccination with mild-to-moderate vaccine-associated reactions. A preliminary study           | 114, 115   |
|        | Novel strain 2009 H1N1  | A/California/07/2009 (H1N1)  | One or two doses of 7.5 µg of MF59-adjuvanted monovalent vaccine resulted in antibody response. Protection should occur within 14 days after the first dose is administered | 116, 117   |
| 2010–1 | None  | For the 2010–2011 season, the following viruses have been selected by the CDC for vaccine production:<br>A/California/7/2009 (H1N1)-like virus,<br>A/Perth/16/2009 (H3N2)-like virus,<br>and B/Brisbane/60/2008-like virus | None  | 118, 119   |

a The strains mentioned are not generally identified as either reference or prototype strains since much of the literature does not refer to them as such. Note also that vaccine strains are not fully described in the literature. Viruses and vaccines are not tabulated for interim periods including 1920–1940, 1948–9, 1959–67, 1970–6, and 1990–6.

due to the Hong Kong flu in the US.<sup>[1,36]</sup> Although the Hong Kong flu virus HA antigen differed from its antecedent Asian virus strain, it had the same (N2) NA antigen. The impact of Hong Kong flu varied in different regions of the world and was mediated in part by differences in prior N2 immunity that likely contributed to the 1968 pandemic.<sup>[123-126]</sup>

In 1976, a potentially epidemic influenza virus (H1N1) was isolated. A high-yield genetic reassortant virus (termed X-53) was isolated and used as a vaccine strain for 3000 people. A subsequent isolate was selected from X-53 stocks, termed X-53a, and this isolate was used for the vaccination of 43 million people.<sup>[1]</sup> In the following year, 1977, the ‘Russian flu’ or ‘red flu’ pandemic commenced and spread from the Soviet Union to other countries, including northeastern China, although there is speculation that red flu may have originated in China.<sup>[1,96]</sup> Its rapid spread was mostly restricted to persons less than 25 years of age and it resulted in mild disease. It had lower cross-reactivity with the subsequent H2N2 and H3N2 subtypes that then successively became the dominant strains. Nucleotide sequencing studies showed that the red flu virus nucleic acid sequences were close to the virus that was pandemic 20 years before and had not run the gauntlet of natural or even *in vitro* growth mutations during the intervening 20 years. Thus, the origin of this virus remains a mystery.<sup>[1,127]</sup>

Influenza epidemics occurred between 1979 and 2008, and several are indicated in table III. The 2009 H1N1 influenza virus pandemic HA gene was derived from ‘classical swine H1N1’ virus and showed both highly altered and conserved antigenicity compared with the 1918 homologs. This suggests that there should be several common cross-reactive neutralizing antibodies for HAs of both viruses, and this is indeed the case.<sup>[4,128,129]</sup> In addition, viruses derived from the 1930s–1940s also harbored epitopes derived from the 1918 pandemic viruses and were found in the 2009 H1N1 viruses. Changes that have occurred in HA since the 1918 pandemic include loss of several N-glycosylation sites; however, new sites were produced in the 2009 viruses. The expectation is that new antibodies should be detectable in the 2009 pandemic that are specific for some of these new N-glycosylation sites and should neutralize the viruses.<sup>[128]</sup>

### 3. H5N1 and Vaccine Preparedness

#### 3.1 H5N1 on the Radar

Prior to the 2009 H1N1 pandemic, H5N1 was anticipated as the impending pandemic influenza virus A. During 2008, there was direct transmission of H5N1 from birds to humans. The H5N1 virus was virulent in birds and killed 245 humans as of

September 10, 2008, making it one of the most lethal influenza strains in humans at that time. Unprecedented among features of influenza virus strains is that this virus had 10 clades and subclades.<sup>[5,33,55,112,130]</sup> Thus, there was a concern that H5N1 was a potential pandemic threat.<sup>[71,106]</sup> Pre-pandemic preparations were developed by many states, including vaccines for various clades and subclades of H5N1 influenza virus, as well as for several bacterial causes of pneumonia (e.g. *Haemophilus influenzae* and *pneumococcus*).<sup>[107]</sup> Trials of H5N1 vaccines among healthy, young, non-pregnant adults showed them to be safe. However, their immunogenicity and safety were unknown for infants and children, people with chronic illness, older people, and pregnant women. Two vaccines were licensed, one in the US and one in Europe. The record indicates that 16 pharmaceutical corporations commenced production of H5N1 vaccines during 2008. However, the vaccines were not available commercially and were apparently stored and controlled in government stockpiles.<sup>[49,131]</sup> Nonetheless, it should be noted that in 2010, some workers in the field still considered H5N1 a pandemic threat that had not gone away.<sup>[132]</sup>

### 3.2 Pandemic Awareness and Preparedness for the 2009 Pandemic

The events described for H5N1 in 2008 set the stage for pandemic awareness. Indeed, in early 2009, unexpectedly, H1N1 influenza – not H5N1 – became pandemic. Once the H1N1 pandemic was underway and recognized, a concern was that it might lead to strains that could become as virulent and lethal as in the 1918 pandemic.<sup>[71]</sup> Initially, it was considered that increased lethality could potentially occur because of recombination and reassortment with other current strains of influenza that may have been sequestered in various human, bird, or animal sub-populations around the world, though this did not occur. Nevertheless, a key remaining issue that still needs investigation is how H1N1 emerged as the 2009 pandemic virus after the initial H5N1 threat. Incontrovertibly, the degree of preparedness was an important component that reduced the spread of H1N1 influenza and reduced the originally feared mortality rate.

### 3.3 Pandemic Criteria

It is of interest to note three requirements or criteria to ‘call’ an influenza virus ‘pandemic’: the strain is easily transmitted from human to human, is antigenically novel, and results in severe disease.<sup>[133]</sup> There is agreement on the use of the first two criteria; however, not all practitioners use the third criterion,

severe disease, consistently. For example, there may be elevated morbidity due to an influenza strain without increased mortality. Moreover, the financial costs to the individual and to society may be more severe because of the pandemic strain than the seasonal viral strains. Nonetheless, these criteria were promptly incorporated by health service departments, especially the WHO and the CDC, with rapid monitoring of the spread of influenza and appropriate dissemination of the information to the public on an unprecedented scale during the 2009 pandemic. In summary, to combat influenza, key efforts include swift and early identification of pandemic and epidemic strains, estimation of their extent, and implementation of correct therapeutic preparations.<sup>[10]</sup>

## 4. Vaccines and Chemotherapy

### 4.1 Classical Vaccines

In the 1930s and 1940s, Horsfall, Lennette, Ginsberg, Salk, and others made early attempts to produce influenza virus vaccines.<sup>[87,134-140]</sup> These attempts did not always succeed, because of antigenic shift and drift, which were unknown at the time. Once embryonated chicken eggs were used for efficient influenza virus production, progress accelerated in vaccine production. Today, several types of vaccines are used, including inactivated or attenuated vaccines, subunit or split vaccines, and protein-viral RNA complexes.<sup>[36,92,141,142]</sup> Nevertheless, vaccine design depends on understanding the importance of changes in viral diversity over time. Moreover, the composition of annual vaccines should address rapid changes in sequence evolution and cognate vaccines should be swiftly deployed. Table III summarizes vaccines used for several influenza virus infections tabulated from 1944 to 2011, exemplifying the huge effort towards this goal. Expressly monitoring the emergence of vaccine-resistant influenza strains is an important component of these efforts, as vaccine-resistant mutants pose a threat for vaccine effectiveness.<sup>[10,143-145]</sup> A caveat that requires consideration is possible recombination that could occur between live vaccine strains and seasonal influenza strains, potentially generating new viral strains.<sup>[146]</sup> This could occur particularly when there is little immunologic cross-reactivity among the vaccine and epidemiologic strains in the first place. Attempting to keep pace with influenza RNA sequence changes, WHO vaccine updates are made twice annually with recommendations for both the northern and southern hemispheres, based on hemispheric seasonal influenza prevention. For the northern hemisphere, the current strains are A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, and B/Brisbane/60/

2008-like virus. For the southern hemisphere, the current strains are A/California/7/2009 (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/60/2008-like virus.<sup>[147,148]</sup>

The fundamental international vaccine strategy promulgated by the American Academy of Pediatrics Committee on Infectious Diseases is to administer H1N1 vaccine for the following risk groups: pregnant women, persons who live with or provide care for infants less than 6 months old, health-care and emergency medical services personnel, persons aged 6 months to 24 years, and persons aged 25–64 years who have medical conditions that put them at higher risk for influenza-related complications.<sup>[148-150]</sup> Integrated with this strategy, maintenance of high standards of vaccine production, including specificity, safety, and efficacy, is under the direction and scrutiny of several groups, including governments and pharmaceutical corporations. Continued cooperation and communication among these groups is important.<sup>[10,143,144]</sup> However, the profound deterioration of the global financial situation over the past several years, as well as frequent international conflicts during the last 100 years, has detrimentally affected the health of people everywhere.

#### 4.2 Novel Vaccines

Novel vaccine technologies under investigation include defective interfering influenza particles, virus-like particles (Novavax, Inc., Rockville, MD, USA), DNA vaccines (Powder-Ject Vaccines, Inc., Madison, WI, USA), and recombinant HA protein (FluBlok<sup>®</sup>; Protein Sciences Corporation, Meriden, CT, USA). In addition, intracellular antibodies that operate within infected cells to neutralize viral proteins may have efficiency and specificity, compared with circulating antibodies within the host. It is hoped that there will be an increased focus on these technologies in the global plans to further the attack on influenza. Certainly, the appearance of patents in these areas of research is encouraging.<sup>[36,151-158]</sup>

#### 4.3 Chemotherapy

Antiviral treatment is most effective when it is initiated within 48 hours after the onset of illness, and anyone (child or adult) with a pre-existing adverse medical condition should be treated immediately.<sup>[149,150]</sup> Antiviral therapy reduces the duration of illness generally by 1 day, significantly reduces nasal viral shedding, and reduces serious illness and death, especially when treatment is initiated promptly.<sup>[159]</sup> There are two US FDA-approved NA inhibitors, oseltamivir and zanamivir. Oseltamivir is given orally and is easy to administer, and za-

namivir is inhaled. Inhalation is not practical for young children and is contraindicated for patients with reactive airway disease. It is important to monitor spread of antiviral resistance, and the WHO does so. As of December 8, 2009, for example, there were 109 oseltamivir-resistant H1N1 viruses detected worldwide and the majority of reported cases were associated with prior oseltamivir treatment.<sup>[160,161]</sup> In addition, for H1N1 viruses, a combination of the older adamantanes (e.g. amantadine and rimantadine) with oseltamivir is advised because of the increasing proportion of resistance to oseltamivir (but not to zanamivir).<sup>[162,163]</sup>

The urgent need for more effective therapy for H1N1 disease stimulated development of the injectable antiviral NA inhibitor, peramivir. Peramivir is a highly selective NA inhibitor for both influenza A and B viruses, and *in vitro* it appears to have greater potency than either zanamivir or oseltamivir, as indicated by its lower EC<sub>50</sub> (effective concentration required to achieve 50% inhibition) values. In early clinical trials, it was used orally and proved highly effective in decreasing mortality. During the 2009 pandemic, injectable peramivir was utilized, and two phase III clinical trials are underway. However, the caveat for its use is that viral resistance to peramivir can develop, which confers partial cross-resistance to oseltamivir and zanamivir.<sup>[148,164,165]</sup> Other studies of antiviral resistance demonstrated unexpected findings, further stressing the importance of monitoring antiviral resistance. Strangely enough, amantadine-sensitive H1N1 influenza A virus decreased during the 2007–2008 season although amantadine-resistant virus had increased during the prior 2005–2006 season. In contrast, among H3N2 viruses, amantadine resistance predominated at these times.<sup>[160]</sup> Further efforts to address the issue of antiviral resistance utilized the combination of vaccines with chemotherapy. It was hypothesized that the use of vaccines and chemotherapy in concert should reduce mortality and morbidity through these two separate antiviral approaches. An early (1980s) chicken model showed success with this approach, as the use of vaccines reduced the spread of antiviral drug resistance.<sup>[166]</sup> However, during the 1987–1989 influenza seasons, the approach using combination vaccination and amantadine chemotherapy was ineffective and resulted in spread of increased resistance to amantadine.<sup>[104,105,167-168]</sup>

#### 4.4 Novel Therapies

There are novel therapeutic technologies against influenza that are worthy of special note. These target viral RNA, mRNA, and replicative form RNA, and include antisense oligonucleotides, short interfering (si)-RNA, and ribozyme technology.

These methods are advantageous because they have the potential to recognize and degrade specific viral RNA sequences. Moreover, siRNA and ribozymes can be made specific so as not to cause damage to the cell's molecular machinery. In addition, this technology can be delivered into cells from external sources (e.g. by intranasal spray or retroviral carriage), which makes them more apt for specifically knocking down viral RNA and virus gene expression. Furthermore, immunomodulating RNAs are being developed against influenza virus. Immunomodulating RNAs induce the host's innate and adaptive antiviral immunity, including toll-like receptor signaling pathways and inflammatory defenses.<sup>[36,154,158,169-172]</sup>

## 5. Conclusions

Fauci, Morens, and colleagues posed several key questions in their articles on insights for the 21st century that should be learned from the 1918 influenza pandemic.<sup>[17,71,73,107]</sup> These questions related to where the 1918 influenza virus originated, why so many people died, why mortality among the elderly was unexpectedly lower than for the younger population, and what the implications of the three waves of virus attack were, as well as our lack of ability to predict pandemic cycles. It was also noted that we have improved efforts against morbidity and mortality, helped most likely by more than half a century of vaccinations.<sup>[8]</sup> Continual monitoring and increased preparedness are key components of the improvements made during the last century and there are international programs that continue to strengthen and coordinate molecular, virologic, immunologic, and administrative influenza sentinel global networks. The Global Influenza Surveillance Network (Global Influenza Programme) is the primary international network and monitors the spread of influenza under the flag of the WHO and WHO collaborating centers, including the CDC and FDA.<sup>[3,17,71,173-176]</sup> These global efforts against influenza also include the Swiss Institute of Bioinformatics (SIB), the Global Initiative on Sharing Avian Influenza Data (GISAID), and the German Ministry of Food, Agriculture, and Consumer Protection (BMELV).<sup>[177,178]</sup>

From an historical perspective, it is important to mention a forerunner international organization that focused on a panoply of influenza pandemic issues with great foresight. The Office International d'Hygiène Publique (OIHP) was established in 1907 in Rome and in 1947 became the WHO of the UN. The OIHP was the first international health organization of its kind and was based in Paris; it published reports on important health-care recommendations, including a report focused on mitigating pandemics. In 1921, the OIHP published

a set of caveats that were acknowledged 86 years later by the CDC in its 2007 report. There were some differences between the two approaches; however, overall they were in concert. Both reports agreed that for affected individuals there should generally be social distancing with careful ventilation, and that infected individuals should be isolated. They disagreed in that the OIHP's 1921 report recommended public use of facemasks, but the CDC's 2007 report did not. In addition, for infected individuals, the OIHP's 1921 report did not recommend dismissal from school in conjunction with quarantining at home, whereas the CDC's 2007 report did make these recommendations.<sup>[12,179-181]</sup> The key issue was to address the droplet spread of infectious influenza. Daily exposure occurs because people congregate in schools, workplaces, military installations, prisons, hospitals, places where drug abusers meet, doctors' offices, supermarkets, malls, religious congregations, bars, restaurants, entertainment centers, during travel, and of course within families. In addition, people are continually exposed to animals and birds because of farming, having pets, hunting, encroachment by people into animal and bird preserves, and the migration of people, birds, and animals.<sup>[182-185]</sup>

Research and development programs continually strive for improved vaccine composition and timing of when to distribute vaccines for use in pandemics. Studies of the 2009 pandemic suggested some changes in vaccination strategy; some critics stated that the WHO implemented vaccination too soon. There will be additional reviews of this complex area by the International Health Regulations Review Committee, a committee of experts with a broad range of scientific expertise and practical experience in public health.<sup>[186,187]</sup>

## Acknowledgments

We apologize to our colleagues in that although there is a wealth of critical contributions to influenza research, many could not be included because of limitations in the scope of this review. We also wish to express our appreciation to the editors for their advice. We thank Dag Shapshak, MD (Medical University of South Carolina, Charleston, SC, USA) for advice.

We are grateful to Yuri Wolf, PhD, and Anastasia Nikolskaya, PhD (National Center for Biotechnology Information, Bethesda, MD, USA) for their comments and for the influenza virus phylogenetic trees.

Support for this work included: Alzheimer Association, University of California Senate, and National Institutes of Health grants AI07126, CA16042, DA07683, and DA10442 (to Francesco Chiappelli).

The authors report no financial conflicts.

## References

1. Kilbourne ED. Influenza pandemics of the 20th century. *Emerg Infect Dis* 2006; 12 (1): 6-14

2. Bao Y, Bolotov P, Dernovoy D, et al. The Influenza Virus Resource at the National Center for Biotechnology Information. *J Virol* 2008; 82 (2): 596-601
3. Salomon R, Webster RG. The influenza virus enigma. *Cell* 2009; 136: 402-10
4. Dawood FS, Jain S, Finelli L, et al.; Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. *N Engl J Med* 2009; 360 (25): 2605-15
5. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, et al.; INER Working Group on Influenza. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. *N Engl J Med* 2009; 361: 680-9
6. Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A (H1N1) infection in Canada; Canadian Critical Care Trials Group H1N1 Collaborative. *JAMA* 2009 Nov 4; 302 (17): 1872-9
7. Lipsitch M, Lajoux M, O'Hagan JJ, et al. Use of cumulative incidence of novel influenza A/H1N1 in foreign travelers to estimate lower bounds on cumulative incidence in Mexico. *PLoS One* 2009 Sep 9; 4 (9): e6895
8. Centers for Disease Control and Prevention. Updated CDC estimates of 2009 H1N1 influenza cases, hospitalizations and deaths in the United States, April 2009-April 10, 2010 [online]. Available from URL: [http://www.cdc.gov/h1n1flu/estimates\\_2009\\_h1n1.htm](http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm) [Accessed 2011 Apr 1]
9. flucount.org. End of day summary [online]. Available from URL: <http://www.flucount.org> [Accessed 2011 Apr 1]
10. Morens DM, Taubenberger JK, Fauci AS. The 2009 H1N1 pandemic influenza virus: what next? *MBio* 2010; 1 (4): e00211-10
11. WHO. Global alert and response (GAR): influenza A(H1N1) – update 48 [online]. Available from URL: [http://www.who.int/csr/don/2009\\_06\\_12/en/index.html](http://www.who.int/csr/don/2009_06_12/en/index.html) [Accessed 2011 Apr 1]
12. Harris KM, Maurer J, Kellermann AL. Influenza vaccine: safe, effective, and mistrusted. *N Engl J Med* 2010; 363: 2183-5
13. Hampson AW, Mackenzie JS. Preparing for an influenza epidemic: the influenza viruses. *Med J Aust* 2006; 185: S39-43
14. Beran GW. Disease and destiny: mystery and mastery. *Prev Vet Med* 2008 Sep 15; 86 (3-4): 198-207
15. Chow A, Ma S, Ling AE, et al. Influenza-associated deaths in tropical Singapore. *Emerg Infect Dis* 2006; 12: 114-21
16. Cruveilhier L. Action du sérum antipneumococcique au cours de la pneumonie et dans les complications de la grippe. *Ann Inst Pasteur (Paris)* 1919; 33: 448-61
17. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. *J Infect Dis* 2008; 198: 962-70
18. Bishop JF, Murnane MP, Owen R. Australia's winter with the 2009 pandemic influenza A (H1N1) virus. *N Engl J Med* 2009; 361: 2591-4
19. Lessler J, Reich NG, Cummings DAT, and the New York City Department of Health and Mental Hygiene Swine Influenza Investigation Team. Outbreak of 2009 pandemic influenza A (H1N1) at a New York City school. *N Engl J Med* 2009; 361: 2628-36
20. Cauchemez S, Donnelly CA, Reed C, et al. Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States. *N Engl J Med* 2009; 361: 2619-27
21. Ito T, Nelson J, Couceiro SS, et al. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. *J Virol* 1998; 72: 7367-73
22. Easterday BC, Van Reeth K. Swine influenza. In: Straw BE, D'Allaire SD, Mengeling WL, editors. *Diseases of swine*. 8th ed. Ames (IA): Iowa State University Press, 1999: 277-90
23. Thacker E, Janke B. Swine influenza virus: zoonotic potential and vaccination strategies for the control of avian and swine influenzas. *J Infect Dis* 2008; 197: S19-24
24. Kothalawala H, Toussaint MJ, Gruys E. An overview of swine influenza. *Vet Q* 2006; 28: 46-53
25. Shinde V, Bridges CB, Uyeki TM, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. *N Engl J Med* 2009; 360: 1-10
26. Olsen CW. The emergence of novel swine influenza viruses in North America. *Virus Res* 2002; 85: 199-210
27. Lekcharoensuk P, Lager KM, Vemulapalli R, et al. Novel swine influenza virus subtype H3N1, United States. *Emerg Infect Dis* 2006; 12: 787-92
28. Shin JY, Song MS, Lee EH, et al. Isolation and characterization of novel H3N1 swine influenza viruses from pigs with respiratory diseases in Korea. *J Clin Microbiol* 2006; 44: 3923-7
29. Karasin AI, Schutten MM, Cooper LA, et al. Genetic characterization of H3N2 influenza viruses isolated from pigs in North America, 1977-1999: evidence for wholly human and reassortant virus genotypes. *Virus Res* 2000; 68: 71-85
30. Webby RJ, Swenson SL, Krauss SL, et al. Evolution of swine H3N2 influenza viruses in the United States. *J Virol* 2000; 74: 8243-51
31. Karasin AI, West K, Carman S, et al. Characterization of avian H3N3 and H1N1 influenza A viruses isolated from pigs in Canada. *J Clin Microbiol* 2004; 42: 4349-54
32. Campitelli L, Donatelli I, Foni E, et al. Continued evolution of H1N1 and H3N2 influenza viruses in pigs in Italy. *Virology* 1997; 232: 310-8
33. Kamps BS, Reyes-Terán G. Chapter 1: influenza 2006. In: Kamps BS, C Hoffmann C, W Preiser W, editors. *Influenza report 2006* [online]. Available from URL: [www.influenzareport.com](http://www.influenzareport.com) [Accessed 2011 Apr 1]
34. Dias A, Bouvier D, Crépin T, et al. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. *Nature* 2009; 458: 914-8
35. Li OT, Chan MC, Leung CS, et al. Full factorial analysis of mammalian and avian influenza polymerase subunits suggests a role of an efficient polymerase for virus adaptation. *PLoS One* 2009 May 21; 4 (5): e5658
36. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. *Nature* 2009; 459: 931-40
37. Guilligay D, Tarendeau F, Resa-Infante P, et al. The structural basis for cap binding by influenza virus polymerase subunit PB2. *Nat Struct Mol Biol* 2008; 15 (5): 500-6
38. Burgui I, Angüez E, Sonenberg N, et al. Influenza virus mRNA translation revisited: is the eIF4E cap-binding factor required for viral mRNA translation? *J Virol* 2007; 81: 12427-38
39. Conenello GM, Palese P. Influenza A virus PB1-F2: a small protein with a big punch. *Cell Host Microbe* 2007; 2: 207-9
40. Conenello G, Zamarin D, Perrone LA, et al. A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. *PLoS Pathog* 2007; 3: 1414-21
41. Khanna M, Gupta N. Influenza A (H1N1) pandemic: preparedness and clinical management. *Ind J Exp Biol* 2009; 47: 929-32
42. McAuley JL, Hornung F, Boyd KL, et al. Expression of the 1918 influenza A virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. *Cell Host Microbe* 2007; 2: 2240-9
43. Trifonov V, Racaniello V, Rabadan R. The contribution of the PB1-F2 protein to the fitness of influenza A viruses and its recent evolution in the 2009 influenza A (H1N1) pandemic virus. *PLoS Curr* 2009 Aug 21; 1: RRR1006
44. Schnitzler SU, Schnitzler P. An update on swine-origin influenza virus A/H1N1: a review. *Virus Genes* 2009; 39: 279-92
45. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. *Science* 2009; 325: 197-201
46. Niman HL. Swine influenza A evolution via recombination – genetic drift reservoir. *Nature Precedings* 2007 Jul 7 [online]. Available from URL: <http://precedings.nature.com/documents/385/version/1/files/npre2007385-1.pdf> [Accessed 2011 Apr 1]

47. Shen J, Ma J, Wang Q. Evolutionary trends of A (H1N1) influenza virus hemagglutinin since 1918. *PLoS One* 2009 Nov 17; 4 (11): e7789
48. Suarez DL, Senne DA, Banks J, et al. Recombination resulting in virulence shift in avian influenza outbreak, Chile. *Emerg Infect Dis* 2004; 10: 693-9
49. Santibañez S, Fiore AE, Merlin TL, et al. A primer on strategies for prevention and control of seasonal and pandemic influenza. *Am J Public Health* 2009 Oct; 99 Suppl. 2: S216-24
50. Neumann G, Kawaoka Y. Reverse genetics of influenza virus. *Virology* 2001 Sep 1; 287 (2): 243-50
51. McAuley JL, Zhang K, McCullers JA. The effects of influenza A virus PB1-F2 protein on polymerase activity are strain specific and do not impact pathogenesis. *J Virol* 2010 Jan; 84 (1): 558-64
52. Khanna M, Kumar P, Prasad AK. Influenza and its role in apoptosis. *Indian Journal of Allergy Asthma and Immunology* 2001 Jan-Jun; 15 (1): 7-12
53. Uiprasertkul M, Kitphati R, Puthavathana P, et al. Apoptosis and pathogenesis of avian influenza A (H5N1) virus in humans. *Emerg Infect Dis* 2007; 13: 708-12
54. Herold S, Steinmueller M, von Wulffen W, et al. Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. *J Exp Med* 2008; 205: 3065-77
55. Allen JE, Gardner SN, Vitalis EA, et al. Conserved amino acid markers from past influenza pandemic strains. *BMC Microbiology* 2009; 9: 77-100
56. Belshe RB, Morens DM. The origins of pandemic influenza: lessons from the 1918 virus. *N Engl J Med* 2005; 353: 2209-11
57. Finkelstein DB, Mukatira S, Mehta PK, et al. Persistent host markers in pandemic and H5N1 influenza viruses. *J Virol* 2007; 81: 10292-9
58. Chen GW, Chang SC, Mok CK, et al. Genomic signatures of human versus avian influenza A viruses. *Emerg Infect Dis* 2006; 12: 1353-60
59. Chaipan C, Kobasa D, Bertram S, et al. Proteolytic activation of the 1918 influenza virus hemagglutinin. *J Virol* 2009; 83 (7): 3200-11
60. Stieneke-Gröber A, Vey M, Anglikler H, et al. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. *EMBO J* 1992 Jul; 11 (7): 2407-14
61. Reid AH, Fanning TG, Hultin JV, et al. Origin and evolution of the 1918 Spanish influenza virus hemagglutinin gene. *Proc Natl Acad Sci U S A* 1999; 96: 1651-6
62. Cohen J. Pandemic influenza: straight from the pig's mouth. Swine research with swine influenzas. *Science* 2009 Jul 10; 325 (5937): 140-1
63. Khiabani H, Trifonov V, Rabadan R. Reassortment patterns in swine influenza viruses. *PLoS One* 2009; 4 (10): 1-7
64. Qi X, Lu C. Swine influenza virus: evolution mechanism and epidemic characterization. A review [article in Chinese; abstract in English]. *Wei Sheng Wu Xue Bao* 2009 Sep 4; 49 (9): 1138-45
65. Hilleman MR. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. *Vaccine* 2002; 20 (25-26): 3068-87
66. De Jong JC, Rimmelzwaan GF, Fouchier RA, et al. Influenza virus: a master of metamorphosis. *J Infect* 2000; 40 (3): 218-28
67. Ferguson NM, Galvani AP, Bush RM. Ecological and immunological determinants of influenza evolution. *Nature* 2003; 422 (6930): 428-33
68. Varich NL, Gitelman AK, Shilov AA, et al. Differential incorporation of genomic segments into the influenza A virus reassortants in mixed infection. *Vopr Virusol* 2009 Jan-Feb; 54 (1): 7-11
69. Nayak DP, Baloguna RA, Yamada H, et al. Influenza virus morphogenesis and budding. *Virus Res* 2009 Aug; 143 (2): 147-61
70. Fitch WM, Leiter JM, Li XQ, et al. Positive Darwinian evolution in human influenza A viruses. *Proc Natl Acad Sci U S A* 1991 May 15; 88 (10): 4270-4
71. Morens DM, Taubenberger JK, Harvey HA, et al. The 1918 influenza pandemic: lessons for 2009 and the future. *Crit Care Med* 2010 Apr; 38 (4 Suppl.): e10-20
72. Suzuki Y, Nei M. Origin and evolution of influenza virus hemagglutinin genes. *Mol Biol Evol* 2002; 19: 501-9
73. Clemow FG. Epidemic influenza. *Public Health* 1889-90; 2: 358-67
74. Clemow FG. The geography of disease. Cambridge: Cambridge University Press, 1903: 187-203
75. Morens DM, Fauci AS. The 1918 influenza pandemic: insights for the 21st century. *J Infect Dis* 2007; 195: 1018-28
76. Potter CW. A history of influenza. *J Appl Microbiol* 2001; 91 (4): 572-9
77. Hilleman M. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. *Vaccine* 2002; 20: 3068-87
78. Taubenberger JK, Morens DM. 1918 influenza: the mother of all pandemics. *Emerg Infect Dis* 2006; 12 (1): 15-22
79. Cadham FT. The use of a vaccine in the recent epidemic of influenza. *Can Med Assoc J* 1919; 9: 519-27
80. Beveridge WI. The chronicle of influenza epidemics. *Hist Philos Life Sci* 1991; 13 (2): 223-34
81. Center for Infectious Disease Research & Policy [CIDRAP], University of Minnesota. Pandemic influenza: pandemics of the 20th century [online]. Available from URL: [http://www.cidrap.umn.edu/cidrap/content/influenza/panflu/biofacts/panflu.html#\\_Pandemics\\_of\\_the\\_20th\\_Century](http://www.cidrap.umn.edu/cidrap/content/influenza/panflu/biofacts/panflu.html#_Pandemics_of_the_20th_Century) [Accessed 2011 Apr 1]
82. Kilbourne ED, Smith C, Brett I, et al. The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic [published erratum appears in *Proc Natl Acad Sci U S A* 2003 Jan 21; 100 (2): 764]. *Proc Natl Acad Sci U S A* 2002 Aug 6; 99 (16): 10748-52
83. Nobel Media AB. Sir Frank Macfarlane Burnet – biography [online]. Available from URL: [http://nobelprize.org/nobel\\_prizes/medicine/laureates/1960/burnet.html](http://nobelprize.org/nobel_prizes/medicine/laureates/1960/burnet.html) [Accessed 2011 Apr 1]
84. Kendall H. Vaccine innovation: lessons from World War II. *J Public Health Policy* 2006; 27 (1): 38-57
85. UniProt Consortium. Influenza A virus (strain A/USA:Huston/AA/1945 H1N1) [online]. Available from URL: <http://www.uniprot.org/taxonomy/425551> [Accessed 2011 Apr 1]
86. Influenza prophylaxis: prophylactic vaccinations [online]. Available from URL: [http://www.en.influenza.pl/ida/prophylactic\\_vaccinations.html](http://www.en.influenza.pl/ida/prophylactic_vaccinations.html) [Accessed 2011 Apr 1]
87. Francis Jr T, Salk JE, Quilligan Jr JJ. Experience with vaccination against influenza in the spring of 1947. *Am J Public Health* 1947; 37: 1013-6
88. UniProt Consortium. Influenza A virus strains of 1946 [online]. Available from URL: <http://www.uniprot.org/taxonomy/?query=influenza+1946++&sort=score> [Accessed 2011 Apr 1]
89. Viboud C, Tam T, Fleming D, et al. 1951 influenza epidemic, England and Wales, Canada, and the United States. *Emerg Infect Dis* 2006 Apr; 12 (4): 661-8
90. Dauer CC, Serfling RE. Mortality from influenza 1957-1958 and 1959-1960. *Am Rev Respir Dis* 1961; 83 (Suppl.): 15-28
91. Henderson DA, Courtney B, Inglesby TV, et al. Public health and medical responses to the 1957-58 influenza pandemic. *Biosecur Bioterror* 2009; 7 (3): 265-73
92. Williams MC, Davignon L, McDonald JC, et al. Trials of aqueous killed influenza vaccine in Canada, 1968-1969. *Bull World Health Org* 1973; 49: 333-40
93. Alling DW, Blackwelder WC, Stuart-Harris CH. A study of excess mortality during influenza epidemics in the United States, 1968-1976. *Am J Epidemiol* 1981; 113: 30-43
94. Knight V, Couch RB, Douglas RIG, et al. Serological responses and results of natural infectious challenge of recipients of zonal ultracentrifuged influenza A2/Aichi/2/68 vaccine. *Bull World Health Org* 1971; 45: 767-71



95. Gaydos JC, Top FH, Hodder RA, et al. Swine influenza A outbreak, Fort Dix, New Jersey, 1976. *Emerg Infect Dis* 2006 Jan; 12 (1): 23-8
96. Beveridge WIB. Where did red flu come from? *New Scientist* 1978; 23: 790-1
97. Halperin W, Weiss WI, Altman R, et al. A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/75: report of a study and review of the literature. *Am J Public Health* 1979; 69: 1247-50
98. Pons VG, Canter J, Dolin R. Influenza A/USSR/77 (H1N1) on a university campus. *Am J Epidemiol* 2006; 111 (1): 23-30
99. Centers for Disease Control and Prevention. Influenza: People's Republic of China. *MMWR Morb Mortal Wkly Rep* 1978; 27: 24
100. Centers for Disease Control and Prevention. Influenza: United States, USSR, Hong Kong. *MMWR Morb Mortal Wkly Rep* 1978; 27: 16
101. Zhdanov VM, Zakstelskaya LY, Isachenko VI, et al. Return of epidemic AI influenza virus. *Lancet* 1978; 1: 294-5
102. Kendal AP, Joseph JM, Kobayashi G, et al. Laboratory-based surveillance of influenza virus in the United States during the winter of 1977-1978: I. Periods of prevalence of H1N1 and H3N2 influenza A strains, their relative rates of isolation in different age groups, and detection of antigenic variants. *Am J Epidemiol* 1979; 110: 449-61
103. Glezen WP, Keitel WA, Taber LH, et al. Age distribution of patients with medically attended illnesses caused by sequential variants of influenza A/H1N1: comparison to age-specific infection rates, 1978-1989. *Am J Epidemiol* 1991; 133: 296-304
104. Mast EE, Harmon MW, Gravenstein S, et al. Emergence and possible transmission of amantadine resistant viruses during nursing home outbreaks of influenza A (H3N2). *Am J Epidemiol* 1991; 134 (9): 988-77
105. Centers for Disease Control and Prevention. Update on influenza activity – United States and worldwide, with recommendations for influenza vaccine composition for the 1988-89 season. *MMWR Morb Mortal Wkly Rep* 1988; 37: 241-4
106. Webster RG, Peiris M, Chen H, et al. H5N1 outbreaks and enzootic influenza. *Emerg Infect Dis* 2006; 12: 3-8
107. Morens DM, Taubenberger JK, Folkers GK, et al. An historical antecedent of modern guidelines for community pandemic influenza mitigation. *Public Health Rep* 2009; 124: 22-5
108. WHO. Global alert and response (GAR): cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO, 10 September 2008 [online]. Available from URL: [http://www.who.int/csr/disease/avian\\_influenza/country/cases\\_table\\_2008\\_09\\_10/en/index.html](http://www.who.int/csr/disease/avian_influenza/country/cases_table_2008_09_10/en/index.html) [Accessed 2011 Apr 1]
109. US FDA. Influenza virus vaccine composition and lot release [online]. Available from URL: <http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Post-MarketActivities/LotReleases/UCM062928> [Accessed 2011 Apr 1]
110. Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. *N Engl J Med* 2005; 353: 1374-85
111. Kaverin NV, Rudneva IA, Govorkova EA, et al. Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. *J Virol* 2007; 81: 12911-7
112. Peiris JS, de Jong MD, Guan Y. Avian influenza virus (H5N1): a threat to human health. *Clin Microbiol Rev* 2007; 20: 243-67
113. UniProt Consortium. Influenza A virus strains of 2003 [online]. Available from URL: <http://www.uniprot.org/taxonomy/?query=influenza+2003&sort=score> [Accessed 2011 Apr 1]
114. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent influenza A (H1N1) vaccine. *N Engl J Med* 2009; 361: 2405-13
115. CSL Limited. A clinical trial of CSL's 2009 H1N1 influenza vaccine (CSL425) in healthy adults [ClinicalTrials.gov identifier NCT00938639]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: <http://www.clinicaltrials.gov/ct2/show/NCT00938639?id=NCT00938639&rank=1> [Accessed 2011 Apr 1]
116. Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. *N Engl J Med* 2009; 361 (25): 2424-35
117. Braithwaite S, Handrigan MT. Novel H1N1 influenza. *Emerg Med Rep* 2010; 31: 1-11
118. Centers for Disease Control and Prevention. Laboratory confirmed influenza-associated hospitalizations and deaths from August 30 2009 to April 3, 2010 [online]. Available from URL: <http://www.cdc.gov/h1n1flu/updates/us/#totalcases> [Accessed 2011 Apr 1]
119. WHO. Global alert and response (GAR): pandemic (H1N1) 2009 [online]. Available from URL: <http://www.who.int/csr/disease/swineflu/en/index.html> [Accessed 2011 Apr 1]
120. Chien YW, Klugman KP, Morens DM. Efficacy of whole-cell killed bacterial vaccines in preventing pneumonia and death during the 1918 influenza pandemic. *J Infect Dis* 2010; 202 (11): 1639-48
121. Rogers DE, Louriya DB, Kilbourne ED. The syndrome of fatal influenza virus pneumonia. *Trans Assoc Am Physicians* 1958; 71: 260-73
122. Choppin PW, Tamm I. Studies of two kinds of virus particles, which comprise influenza A2 virus strains: II. Reactivity with virus inhibitors in normal sera. *J Exp Med* 1960; 112: 921-44
123. Schulman JL, Kilbourne ED. Independent variation in nature of the hemagglutinin and neuraminidase antigens of influenza virus: distinctiveness of the hemagglutinin antigen of Hong Kong-68 virus. *Proc Natl Acad Sci U S A* 1969; 63: 326-33
124. Stuart-Harris C. Epidemiology of influenza in man. *Br Med Bull* 1979; 35: 3-8
125. Monto AS, Kendal AP. Effect of neuraminidase antibody on Hong Kong influenza. *Lancet* 1973; 1: 623-5
126. Viboud C, Grais RF, Lafont BA, et al.; Multinational Influenza Seasonal Morbidity Study Group. Multinational impact of the 1968 Hong Kong pandemic: evidence for a smoldering pandemic. *J Infect Dis* 2005; 192: 223-48
127. Mermel LA. Swine-origin influenza virus in young age groups. *Lancet* 2009; 373: 2108-9
128. Igarashi M, Ito K, Yoshida R, et al. Predicting the antigenic structure of the pandemic (H1N1) 2009 influenza virus hemagglutinin. *PLoS One* 2010 Jan 1; 5 (1): e8553
129. Krause JC, Tumpey TM, Huffman CJ, et al. Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. *J Virol* 2010 Mar; 84 (6): 3127-30
130. Alexander DJ. An overview of the epidemiology of avian influenza. *Vaccine* 2007; 25: 5637-44
131. Center for Infectious Disease Research & Policy [CIDRAP], University of Minnesota. Launch of WHO H5N1 vaccine stockpile still awaited [online]. Available from URL: <http://www.cidrap.umn.edu/cidrap/content/influenza/panflu/news/may1608vaccine.html> [Accessed 2011 Apr 1]
132. Sambhara S, Poland GA. H5N1 avian influenza: preventive and therapeutic strategies against a pandemic. *Ann Rev Med* 2010; 61: 187-98
133. McCullers JA. Preparing for the next influenza pandemic. *Pediatr Infect Dis J* 2008 Oct; 27 (10 Suppl.): S57-9
134. Shope RE. Swine influenza: I. Experimental transmission and pathology. *J Exp Med* 1931; 54: 349-59
135. Shope RE. Swine influenza: III. Filtration experiments and etiology. *J Exp Med* 1931; 54: 373-85
136. Lewis PA, Shope RE. Swine influenza: II. A hemophilic bacillus from the respiratory tract of infected swine. *J Exp Med* 1931; 54: 361-71
137. Horsfall FL, Lennette EH, Rickard RE. A complex vaccine against influenza A virus. *J Exp Med* 1941; 73: 335-55

138. Horsfall Jr FL, Lennette EH. A complex vaccine effective against different strains of influenza virus. *Science* 1940; 91: 492-5
139. Horsfall FL, Lennette EH. The synergism of human influenza and canine distemper viruses in ferrets. *J Exp Med* 1941; 72: 247-59
140. Ginsberg HS, Horsfall FL. Concurrent infection with influenza virus and mumps virus or pneumonia virus of mice as bearing on the inhibition of virus multiplication by bacterial polysaccharides. *J Exp Med* 1949 Jan; 89 (1): 37-52
141. Couch RB. Seasonal inactivated influenza virus vaccines. *Vaccine* 2008; 26 (Suppl. 4): D5-9
142. Legastelois I, Garcia-Sastre A, Palese P, et al. Preparation of genetically engineered A/H5N1 and A/H7N1 pandemic vaccine viruses by reverse genetics in a mixture of Vero and chicken embryo cells. *Influenza Other Respir Viruses* 2007 May; 1 (3): 95-104
143. Biere B, Schweiger B. Molecular analyses of human influenza viruses: circulation of new variants since 1995/96. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 2008 Sep; 51 (9): 1050-60
144. Iwami S, Suzuki T, Takeuchi Y. Paradox of vaccination: is vaccination really effective against avian flu epidemics? *PLoS One* 2009; 4 (3): e4915
145. Schweiger B, Bruns L, Meixenberger K. Reassortment between human A(H3N2) viruses is an important evolutionary mechanism. *Vaccine* 2006 Nov 10; 24 (44-46): 6683-90
146. He CQ, Han GZ, Wang D, et al. Homologous recombination evidence in human and swine influenza A viruses. *Virology* 2008 Oct 10; 380 (1): 12-20
147. WHO. Global alert and response (GAR): recommendations for influenza vaccines [online]. Available from URL: <http://www.who.int/csr/disease/influenza/vaccinerecommendations/en/index.html> [Accessed 2011 Apr 1]
148. Centers for Disease Control and Prevention. 2009 H1N1 vaccination recommendations [online]. <http://www.cdc.gov/h1n1flu/vaccination/acip.htm> [Accessed 2011 Apr 1]
149. Fiore AE, Shay DK, Broder K, et al.; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. *MMWR Recomm Rep* 2008; 57 (RR-7): 1-60
150. American Academy of Pediatrics. Implementation guidance – seasonal influenza [online]. Available from URL: [http://www.aap.org/immunization/illnesses/flu/ImplementationGuidance\\_Flu.pdf](http://www.aap.org/immunization/illnesses/flu/ImplementationGuidance_Flu.pdf) [Accessed 2011 Apr 1]
151. Lo AS, Zhu Q, Marasco WA. Intracellular antibodies (intrabodies) and their therapeutic potential. *Handb Exp Pharmacol* 2008; 181: 343-73
152. Mann A, Marriott AC, Balasingam S, et al. Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection. *Vaccine* 2006 May 15; 24 (20): 4290-6
153. DeVincenzo JP. RNA interference strategies as therapy for respiratory viral infections. *Pediatr Infect Dis J* 2008 Oct; 27 (10 Suppl.): S118-22
154. Saravolac EG, Wong JP. Recent patents on development of nucleic acid-based antiviral drugs against seasonal and pandemic influenza virus infections. *Recent Pat Antiinfect Drug Discov* 2007 Jun; 2 (2): 140-7
155. King Jr JC, Cox MM, Reisinger K, et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. *Vaccine* 2009; 27 (47): 6589-94
156. Mahmood K, Bright RA, Mytelle N, et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. *Vaccine* 2008; 26 (42): 5393-9
157. Drape RJ, Macklin MD, Barr LJ, et al. Epidermal DNA vaccine for influenza is immunogenic in humans. *Vaccine* 2006 May 22; 24 (21): 4475-81
158. Schotsaert M, De FM, Fiers W, et al. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. *Expert Rev Vaccines* 2009; 8: 499-508
159. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. *Clin Infect Dis* 2007; 45: 1568-75
160. Furuse Y, Suzuki A, Shimizu M, et al. Reassortment between amantadine-resistant and -sensitive H1N1 influenza A viruses generated an amantadine-sensitive virus during the 2007-2008 season. *J Infect Disease* 2009 Dec 1; 200 (11): 1766-73
161. WHO. Global alert and response (GAR): Antiviral drugs for pandemic (H1N1) 2009: definitions and use [online]. Available from URL: [http://www.who.int/csr/disease/swineflu/frequently\\_asked\\_questions/antivirals/definitions\\_use/en/index.html](http://www.who.int/csr/disease/swineflu/frequently_asked_questions/antivirals/definitions_use/en/index.html) [Accessed 2011 Apr 1]
162. Moscona A. Neuraminidase inhibitors for influenza. *N Engl J Med* 2005; 353: 1363-73
163. Gerloff NA, Kremer JR, Mossong J, et al. Genomic diversity of oseltamivir-resistant influenza virus A (H1N1), Luxembourg, 2007-08. *Emerg Infect Dis* 2009 Sep; 15 (9): 1523-4
164. Smee DF, Sidwell RW. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza. *Exp Opin Investig Drugs* 2002; 11 (6): 859-69
165. BioCryst Pharmaceuticals. Safety study of IV peramivir in hospitalized subjects with confirmed or suspected influenza [ClinicalTrials.gov identifier NCT00957996]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: <http://www.clinicaltrials.gov/ct2/show/NCT00957996?id=NCT00957996&rank=1> [Accessed 2011 Apr 1]
166. Webster RG, Kawaoka Y, Bean WJ, et al. Chemotherapy and vaccination: a possible strategy for the control of highly virulent influenza virus. *J Virol* 1985 July; 55 (1): 173-6
167. Longini Jr IM, Halloran ME, Nizam A, et al. Containing pandemic influenza with antiviral agents. *Am J Epidemiol* 2004; 159 (7): 623-33
168. Dharan NJ, Patton M, Siston AM, et al. Outbreak of antiviral drug-resistant influenza A in long-term care facility, Illinois, USA, 2008. *Emerg Infect Dis* 2009 Dec; 15 (12): 1973-6
169. Lazarev VN, Shmarov MM, Zakhartchouk AN, et al. Inhibition of influenza A virus reproduction by a ribozyme targeted against PB1 mRNA. *Antiviral Res* 1999 May; 42 (1): 47-57
170. Sui HY, Zhao GY, Huang JD, et al. Small interfering RNA targeting m2 gene induces effective and long term inhibition of influenza A virus replication. *PLoS One* 2009 May 22; 4 (5): e5671
171. Bitko V, Barik S. Nasal delivery of siRNA. *Methods Mol Biol* 2008; 442: 75-82
172. Wong JP, Christopher ME, Salazar AM, et al. Broad-spectrum and virus-specific nucleic acid-based antivirals against influenza. *Front Biosci (Schol Ed)* 2010 Jan 1; 2: 791-800
173. Zhang S, Yan P, Winchester B, et al. Transmissibility of the 1918 pandemic influenza in Montreal and Winnipeg of Canada. *Influenza Other Respir Viruses* 2010 Jan; 4 (1): 27-31
174. HHS.gov. HHS pandemic influenza plan [online]. Available from URL: <http://www.hhs.gov/pandemicflu/plan/> [Accessed 2011 Apr 1]
175. Stohr K. Overview of the WHO Global Influenza Programme. *Dev Biol (Basel)* 2003; 115: 3-8
176. WHO. Global alert and response (GAR): WHO collaborating centres for influenza and essential regulatory laboratories [online]. Available from URL: <http://www.who.int/csr/disease/influenza/collabcentres/en/index.html> [Accessed 2011 Apr 1]
177. Butler D. Flu database rocked by legal row. *Nature* 2009 Aug; 460: 786-7 [online]. Available from URL: <http://www.nature.com/news/2009/090812/pdf/460786b.pdf> [Accessed 2011 Apr 1]
178. Center for Infectious Disease Research & Policy [CIDRAP], University of Minnesota. German Government to host flu database [media release]. 2009 Oct 20 [online]. Available from URL: <http://www.cidrap.umn.edu/cidrap/content/influenza/general/news/oct2009gisaid.html> [Accessed 2011 Apr 1]
179. American Public Health Association. Influenza: report of a special committee of the American Public Health Association. *J Am Med Assoc* 1918; 71: 2068-73

- 
180. Pottevin H. Rapport sur la pandémie grippale de 1918-1919 présenté au Comité Permanent de l'Office Internationale d'Hygiène Publique. Bulletin de l'Office Internationale d'Hygiène Publique 1921; 13: 125-81
181. Flu.gov. Community strategy for pandemic influenza mitigation [online]. Available from URL: <http://pandemicflu.gov/professional/community/commitigation.html> [Accessed 2011 Apr 1]
182. Baral S, Sherman SG, Millson P, et al. Vaccine immunogenicity in injecting drug users: a systematic review. *Lancet Infect Dis* 2007; 7: 667-74
183. Boschini A, Longo B, Caselli F, et al. An outbreak of influenza in a residential drug-rehabilitation community. *J Med Virol* 2006; 78: 1218-22
184. Baral S, Sherman SG, Millson P, et al. Vaccine immunogenicity in injecting drug users: a systematic review. *Lancet Infect Dis* 2007 Oct; 7 (10): 667-74
185. Stancliff S, Salomon N, Perlman DC, et al. Provision of influenza and pneumococcal vaccines to injection drug users at a syringe exchange. *J Subst Abuse Treat* 2000 Apr; 18 (3): 263-5
186. Bragstad K, Nielsen LP, Fomsgaard A. The evolution of human influenza A viruses from 1999 to 2006: a complete genome study. *Virology* 2008 Mar 7; 5: 40-53
187. Zarocostas J. External committee is to look at criticisms of WHO's management of H1N1 pandemic. *BMJ* 2010; 340: 2342-3
- 

Correspondence: Professor *Paul Shapshak*, Division of Infectious Disease, University of South Florida Health, Tampa General Hospital, 2 Columbia Drive, Tampa, FL 33606, USA.  
E-mail: [pshapshak@gmail.com](mailto:pshapshak@gmail.com)